EP4347791A4 - Médicament pour thérapie génétique et à base de cellules géniques - Google Patents

Médicament pour thérapie génétique et à base de cellules géniques

Info

Publication number
EP4347791A4
EP4347791A4 EP22816533.8A EP22816533A EP4347791A4 EP 4347791 A4 EP4347791 A4 EP 4347791A4 EP 22816533 A EP22816533 A EP 22816533A EP 4347791 A4 EP4347791 A4 EP 4347791A4
Authority
EP
European Patent Office
Prior art keywords
gene
medicines
based therapy
cell
gene cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22816533.8A
Other languages
German (de)
English (en)
Other versions
EP4347791A1 (fr
Inventor
Ajsylu Ildarovna Mullagulova
Alisa Almazovna Shajmardanova
Dar'ya Sergeevna Chulpanova
Valeriya Valer'evna Solov'eva
Yana Olegovna Muhamedshina
Aleksandr Aleksandrovich Kostennikov
Al'bert Anatol'evich Rizvanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University"
Federal State Autonomus Educational Institution Of Higher Learning Kazan Volga Region Federal Univ
Original Assignee
Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University"
Federal State Autonomus Educational Institution Of Higher Learning Kazan Volga Region Federal Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University", Federal State Autonomus Educational Institution Of Higher Learning Kazan Volga Region Federal Univ filed Critical Federal State Autonomus Educational Institution Of Higher Learning "kazan Volga Region Federal University"
Publication of EP4347791A1 publication Critical patent/EP4347791A1/fr
Publication of EP4347791A4 publication Critical patent/EP4347791A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
EP22816533.8A 2021-06-01 2022-05-27 Médicament pour thérapie génétique et à base de cellules géniques Pending EP4347791A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021115696A RU2769577C1 (ru) 2021-06-01 2021-06-01 Препарат для лечения метахроматической лейкодистрофии и способ ее лечения
PCT/RU2022/000180 WO2022255906A1 (fr) 2021-06-01 2022-05-27 Médicament pour thérapie génétique et à base de cellules géniques

Publications (2)

Publication Number Publication Date
EP4347791A1 EP4347791A1 (fr) 2024-04-10
EP4347791A4 true EP4347791A4 (fr) 2025-07-09

Family

ID=81076125

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22816533.8A Pending EP4347791A4 (fr) 2021-06-01 2022-05-27 Médicament pour thérapie génétique et à base de cellules géniques

Country Status (3)

Country Link
EP (1) EP4347791A4 (fr)
RU (1) RU2769577C1 (fr)
WO (1) WO2022255906A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079361A1 (fr) * 2022-10-14 2024-04-18 Neuway Pharma Gmbh Capsule à base de protéines ou de peptides (ppc), de préférence une vlp, chargée d'un arnm et procédé de production et de purification de celle-ci
WO2025084951A1 (fr) * 2023-10-16 2025-04-24 Joint Stock Company "Axelgen" Construction génétique recombinée, virus adéno-associé pour le traitement de la leucodystrophie métachromatique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142932A1 (fr) * 2019-06-10 2020-12-17 Homology Medicines, Inc. Compositions de virus adeno-associes pour transfert de gene arsa et leurs procedes d'utilisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013357812B2 (en) * 2012-12-11 2019-10-10 Centogene Gmbh Method for the diagnosis of metachromatic leukodystrophy
BR112021021908A2 (pt) * 2019-05-03 2022-02-01 Univ Pennsylvania Composições úteis no tratamento da leucodistrofia metacromática

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3142932A1 (fr) * 2019-06-10 2020-12-17 Homology Medicines, Inc. Compositions de virus adeno-associes pour transfert de gene arsa et leurs procedes d'utilisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GOURAV ROY ET AL: "Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting", 11 May 2021 (2021-05-11), pages 1 - 2, XP093279474, Retrieved from the Internet <URL:https://s203.q4cdn.com/877117837/files/doc_news/archive/7a3a2804-23f6-4ad1-98d5-a0828099c284.pdf> *
JUDITH B�HRINGER ET AL: "Enzymatic characterization of novel arylsulfatase A variants using human arylsulfatase A-deficient immortalized mesenchymal stromal cells", HUMAN MUTATION, JOHN WILEY & SONS, INC, US, vol. 38, no. 11, 6 September 2017 (2017-09-06), pages 1511 - 1520, XP071975898, ISSN: 1059-7794, DOI: 10.1002/HUMU.23306 *
See also references of WO2022255906A1 *
SHAIMARDANOVA ALISA A. ET AL: "Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches", FRONTIERS IN MEDICINE, vol. 7, 1 January 2020 (2020-01-01), pages 576221, XP093041645, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606900/pdf/fmed-07-576221.pdf> DOI: 10.3389/fmed.2020.576221 *
SWEENEY NATHAN PAUL ET AL: "Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector", MOLECULAR THERAPY, vol. 24, no. 7, 1 July 2016 (2016-07-01), United States, pages 1227 - 1236, XP093279493, ISSN: 1525-0016, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S1525001616303550> DOI: 10.1038/mt.2016.91 *

Also Published As

Publication number Publication date
RU2769577C1 (ru) 2022-04-04
EP4347791A1 (fr) 2024-04-10
WO2022255906A1 (fr) 2022-12-08

Similar Documents

Publication Publication Date Title
EP4347791A4 (fr) Médicament pour thérapie génétique et à base de cellules géniques
Terkeltaub et al. Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
IL288755A (en) Compositions and methods for biological delivery vehicles
DK4054662T3 (da) Hydrofile medicinske produkter og hydratiseringsmedier til hydratisering heraf
IL291191A (en) Cdk inhibitors and their use as pharmaceuticals
IL320856A (en) Pharmaceutical combinations and their uses
ZA202400656B (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
EP4324438C0 (fr) Cabine de physiothérapie cryogénique et système de cabine de physiothérapie cryogénique
IL297900B2 (en) A compound with KDM5 inhibitory activity and its pharmaceutical use
IL307997A (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
EP4449904A4 (fr) Système d&#39;alimentation en aérosol et atomiseur associé
JOP20230017A1 (ar) أجسام مضادة لأميلويد بيتا
EP4071767A4 (fr) Système d&#39;affichage de prédiction et procédé de traitement
EP3793446A4 (fr) Distribution génique et médicamenteuse à médiation par ultrasons
EP3962878A4 (fr) Corps céramique monolithique et ensemble
EP4396577A4 (fr) Biotest à flux latéral intégré et biocapteur
EP4400117A4 (fr) Méthode de criblage de médicament sénolytique et médicament sénolytique
EP4055175A4 (fr) Promoteurs de cellules auditives internes cochléaires et leurs utilisations
EP4393501A4 (fr) Médicament conjugué à un polypeptide tricyclique et son utilisation
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
EP3677248A4 (fr) Agent anti-âge pour la peau et régulateur de l&#39;expression génique lié au vieillissement
EP4384256A4 (fr) Ensemble d&#39;administration de médicaments pour une administration prolongée de médicaments et une ajustabilité
IL271224A (en) Aminoglycoside derivatives and uses thereof in treating genetic disorders
EP3801493C0 (fr) Système de moulage et de revêtement de comprimés pharmaceutiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250605

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/02 20060101ALI20250530BHEP

Ipc: A61P 25/28 20060101ALI20250530BHEP

Ipc: C12N 7/00 20060101ALI20250530BHEP

Ipc: C12N 15/861 20060101ALI20250530BHEP

Ipc: C12N 5/0775 20100101AFI20250530BHEP